datta_kishalay, New Delhi (2026)

13/08/2026

Recent International publication in Saudia journal of EM .

30/07/2026

Overview of mine :

The editorial discusses recent updates to the clinical guidelines for using activated charcoal (AC) in managing acute oral poisoning.

These updates challenge established paradigms—specifically the traditional one-hour administration window—based on new evidence regarding gastric emptying and drug absorption kinetics.

What I understand :

1. Re-evaluating the 1-Hour Time Limit.

Delayed Gastric Emptying:

Evidence shows that overdoses often delay gastric emptying significantly. This can be due to the direct effects of specific drugs (like opioids and antimuscarinic agents) or simply the physical burden of a large number of tablets.

Prolonged Presence in the Stomach:

Endoscopic studies reveal that substantial amounts of ingested substances can remain in the stomach for 4 to 12 hours post-ingestion.

New Recommendation:

AC administration should no longer be based strictly on the time elapsed since ingestion. Instead, decisions must incorporate the specific toxicological properties of the substance, the pharmaceutical formulation, and an individualized patient risk assessment.

2. Additional Dosing
Standard Dosing:

The baseline dose remains unchanged at 50 g for adults or 1 g/kg for pediatric patients (ideally at a 10:1 ratio of AC to the toxic substance).

Supplemental Dose: A second dose (either full or half) can now be considered if there is suspicion or evidence of ongoing gastrointestinal absorption. There is no strict time window for this additional dose; it should be tailored to the patient's clinical progression.

3. Multiple-Dose Activated Charcoal (MDAC):

MDAC is designed to enhance the elimination of toxins by interrupting enterohepatic or enteroenteric recirculation. The workgroup issued specific recommendations based on the substance:

Strongly Recommended:

Dapsone, phenobarbital, theophylline, and aminophylline.

Weakly Recommended:

Carbamazepine, cardiac glycosides, colchicine, phenytoin, and thallium.

Future Directions and Research Needs
The authors conclude that while these updated guidelines greatly optimize gastrointestinal decontamination, significant research gaps remain.

Further investigation is critically needed for special populations where current evidence is limited, including:

Patients with morbid obesity

Patients with prior bariatric surgery

Pregnant individuals

Children and older adults.

Dr Datta .